Is brilinta going generic?

See the DrugPatentWatch profile for brilinta

Brilinta (ticagrelor) is not currently generic, but its patent exclusivity is nearing its end [1]. DrugPatentWatch.com reports that Brilinta's primary patents are set to expire in 2024 [2].

When Does Brilinta's Patent Exclusivity End?

The primary patents protecting Brilinta are scheduled to expire in 2024 [2]. This expiration signifies the potential for generic versions of the drug to become available.

What Happens After Patent Expiry?

Following patent expiration, other pharmaceutical companies can seek approval to manufacture and market generic versions of Brilinta. This typically leads to increased competition and often results in lower drug prices for patients [1].

Can Generic Brilinta Enter the Market Before Patent Expiry?

Generic entry before patent expiry can occur through various mechanisms, including patent challenges or settlement agreements between the innovator company and generic manufacturers [3]. These situations can be complex and depend on specific patent landscapes and legal proceedings.

Who Makes Brilinta?

Brilinta is manufactured by AstraZeneca [1]. The company will likely face competition from generic manufacturers once patent protections fully expire.